Introduction Autoimmune hepatitis (AIH) is a severe hepatopathy often progressing to end-stage liver disease. Evidence implicates the involvement of both CD4 and CD8 T cell responses in its pathogenesis. There are a number of different inhibitory molecules expressed by T cells that can attenuate T cell receptor signalling. These include cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and the recently described T cell immunoglobulin and mucin domain-3 (Tim-3). Whether a disturbed expression of these inhibitory molecules can result in an increased susceptibility to autoimmune liver disease is unknown.
Aims to evaluate the expression of CTLA-4, PD-1, and Tim-3 by CD4 and CD8 T cells in patients with autoimmune hepatitis.
Methods 12 ANA/SMA+ AIH patients (6 females, median age: 14 years) and 6 healthy subjects (HS, four females, median age: 26.4 years) were studied. Phenotype of CD4 and CD8 T cells was determined by flow cytometry using monoclonal antibodies against CD4, CD8, PD-1 and Tim-3. Expression of CTLA-4 was determined by intracellular staining.
Results The frequency of Tim-3pos and PD-1pos cells within CD4 and CD8 T cells was lower in AIH (CD4posTim-3pos: 1.6±0.3; CD4posPD-1pos: 4.8±0.5; CD8posTim-3pos: 9.6±1.6; CD8posPD-1pos: 6.7±0.7) than in HS (CD4posTim-3pos: 6.2±0.8, PposPD-1pos: 8.1±1.9, P=0.04; CD8posTim-3pos: 15.8±1.8, P=0.04; CD8posPD-1pos: 12.6±1.4 6.7±0.7, Ppos cells between the two groups of subjects. While in health dually Tim-3 and PD-1 positive populations are recognisable (CD4posTim-3posPD-1pos: 0.7±0.1; CD8posTim-3posPD-1pos: 1.7±0.4), they are reduced in AIH (CD4posTim-3posPD-1pos: 0.4±0.1, p=0.007; CD8posTim-3posPD-1pos: 0.9±0.3, p=0.03).
Conclusion AIH patients have fewer PD-1 and Tim3 positive cells within both CD4 and CD8 T cells. Defective expression of these negative immune-regulatory molecules may contribute to breakdown of tolerance, possibly accounting for the initiation and/or perpetuation of the autoimmune liver attack.
Competing interests None declared.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.